

In the claims:

1-37. Cancelled.

38. (Currently Amended) A method for modifying glucose metabolism in a glucose intolerant animal, comprising administering to the animal, in a single daily oral dosage, a composition including one or more protease inhibitors which inhibit DPIV-mediated proteolysis with a K_i of less than about 10 nM in an amount sufficient to modify glucose metabolism but not sufficient to suppress the immune system of the animal.

39. (Currently Amended) A method for modifying glucose metabolism in a glucose intolerant animal, comprising administering to the animal, in a single daily oral dosage, a composition including one or more protease inhibitors which inhibit the proteolysis of glucagon-like peptide 1 (GLP-1) with a K_i of less than about 10 nM in an amount sufficient to modify glucose metabolism but not sufficient to suppress the immune system of the animal.

40. (Currently Amended) A method for modifying metabolism of a peptide hormone in a glucose intolerant animal, comprising administering to the animal a composition, in a single daily oral dosage, including one or more inhibitors of dipeptidylpeptidase IV (DPIV), wherein the inhibitor inhibits DPIV with a K_i of less than about 10 nM, in an amount sufficient to increase the plasma half-life of the peptide hormone, which peptide hormone is selected from glucagon-like peptide 2 (GLP-2), growth hormone-releasing factor (GHRF), vasoactive intestinal peptide (VIP), peptide histidine isoleucine (PHI), pituitary adenylate cyclase activating peptide (PACAP), gastric inhibitory peptide (GIP), helodermin, Peptide YY and neuropeptide Y, wherein the composition is administered in an amount sufficient to modify the metabolism of the peptide hormone but not sufficient to suppress the immune system of the animal.

41. (Currently Amended) A method for modifying glucose metabolism of a glucose intolerant animal, comprising administering to the animal a composition including a boronyl peptidomimetic inhibitor of a peptide selected from Pro-Pro, Ala-Pro, and (D)-Ala-(L)-Ala in an amount sufficient to modify glucose metabolism but not sufficient to suppress the immune system of the animal.

42. (Currently Amended) The method of claim 41, wherein, the glucose intolerance in the animal is a result of a deletion or disruption of the gene encoding for a glucagon type peptide 1 (GLP-1) receptor.

43-45. (Cancelled)

46. (Currently Amended) The method of any one of claims 38, 39, 40, or 41, wherein administering the inhibitor reduces one or more of insulin resistance, glucose intolerance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, or hyperlipoproteinemia.

47. (Currently Amended) The method of any one of claims 38, 39, 40, or 41, wherein the inhibitor has an EC50 for modification of glucose metabolism which is at least one order of magnitude less than its EC50 for immunosuppression.

48. (Currently Amended) The method of any one of claims 38, 39, 40, or 41, wherein the inhibitor has an EC50 for inhibition of glucose tolerance in the nanomolar or less range.

49. (Currently Amended) The method of any one of claims 38, 39, 40, or 41, wherein the inhibitor has an EC50 for immunosuppression in the μM or greater range.


50. (Currently Amended) The method of any one of claims 38, 39, 40, or 41, wherein the inhibitor has a K_i for DPIV inhibition of 0.5 nM or less.

51. (Currently Amended) The method of any one of claims 38, 39, or 40, wherein the inhibitor is peptidomimetic of a peptide selected from Pro-Pro, Ala-Pro, and (D)-Ala-(L)-Ala.

52. (Currently Amended) The method of any one of claims 38, 39, 40 or 41, wherein the inhibitor has a molecular weight of less than 7500 amu.

53. (Currently Amended) The method of claim ~~38, 39, 40 or~~ 41, wherein the inhibitor is administered orally.

54. (Currently Amended) The method of any one of claims 38, 39, 40, or 41, wherein the inhibitor is represented by the general Formula VII:




wherein,


A represents a 4-8 membered heterocycle including a N and a C α carbon;

Z represents C or N;

W represents -CH=NR₅,



R₁ represents a C-terminally linked amino acid residue or amino acid analog, or a C-terminally linked peptide or peptide analog, or an amino-protecting group,



R₂ is absent or represents one or more substitutions to the ring A, each of which can


independently be a halogen, a lower alkyl, a lower alkenyl, a lower alkynyl, a carbonyl, a thiocarbonyl, an amino, an acylamino, an amido, a cyano, a nitro, an azido, a sulfate, a sulfonate, a sulfonamido, -(CH₂)_m-R₇, -(CH₂)_m-OH, -(CH₂)_m-O-lower alkyl, -(CH₂)_m-O-lower alkenyl, -(CH₂)_n-O-(CH₂)_m-R₇, -(CH₂)_m-SH, -(CH₂)_m-S-lower alkyl, -(CH₂)_m-S-lower alkenyl, or -(CH₂)_n-S-(CH₂)_m-R₇;

if Z is N, R₃ represents a hydrogen;

if Z is C, R₃ represents a hydrogen or a halogen, a lower alkyl, a lower alkenyl, a lower alkynyl, a carbonyl, a thiocarbonyl, an amino, an acylamino, an amido, a cyano, a nitro, an azido, a sulfate, a sulfonate, a sulfonamido, -(CH₂)_m-R₇, -(CH₂)_m-OH, -(CH₂)_m-O-lower alkyl, -(CH₂)_m-O-lower alkenyl, -(CH₂)_n-O-(CH₂)_m-R₇, -(CH₂)_m-SH, -(CH₂)_m-S-lower alkyl, -(CH₂)_m-S-lower alkenyl, or -(CH₂)_n-S-(CH₂)_m-R₇;

R_5 represents a hydrogen, an alkyl, an alkenyl, an alkynyl, $-C(X_1)(X_2)X_3$, $-(CH_2)_m-R_7$, $-(CH_2)_n-OH$, $-(CH_2)_n-O-alkyl$, $-(CH_2)_n-O-alkenyl$, $-(CH_2)_n-O-alkynyl$, $-(CH_2)_n-O-(CH_2)_m-R_7$, $-(CH_2)_n-SH$, $-(CH_2)_n-S-alkyl$, $-(CH_2)_n-S-alkenyl$, $-(CH_2)_n-S-alkynyl$, $-(CH_2)_n-S-(CH_2)_m-R_7$, $-C(O)C(O)NH_2$, or $-C(O)C(O)OR'_7$;

R_6 represents a hydrogen, a halogen, an alkyl, an alkenyl, an alkynyl, an aryl, $-(CH_2)_m-R_7$, $-(CH_2)_m-OH$, $-(CH_2)_m-O-alkyl$, $-(CH_2)_m-O-alkenyl$, $-(CH_2)_m-O-alkynyl$, $-(CH_2)_m-O-(CH_2)_m-R_7$, $-(CH_2)_m-SH$, $-(CH_2)_m-S-alkyl$, $-(CH_2)_m-S-alkenyl$, $-(CH_2)_m-S-alkynyl$, $-(CH_2)_m-S-(CH_2)_m-R_7$,



R_7 represents, for each occurrence, a substituted or unsubstituted aryl, aralkyl, cycloalkyl, cycloalkenyl or heterocyclyl;

R'_7 represents, for each occurrence, hydrogen, or a substituted or unsubstituted alkyl, alkenyl, aryl, aralkyl, cycloalkyl, cycloalkenyl or heterocyclyl;

R_8 and R_9 each independently represent hydrogen, alkyl, alkenyl, $-(CH_2)_m-R_7$, $-C(=O)-alkyl$, $-C(=O)-alkenyl$, $-C(=O)-alkynyl$, or $-C(=O)-(CH_2)_m-R_7$,

or R_8 and R_9 taken together with the N atom to which they are attached complete a heterocyclic ring having from 4 to 8 atoms in the ring structure;

R_{50} represents O or S;

R_{51} represents N_3 , SH, NH_2 , NO_2 or OR'_7 ;

R_{52} represents hydrogen, a lower alkyl, an amine, OR'_7 , or a pharmaceutically acceptable salt, or R_{51} and R_{52} taken together with the phosphorous atom to which they are attached complete a heterocyclic ring having from 5 to 8 atoms in the ring structure;

Y_1 and Y_2 can independently or together be OH or an alkoxy, or taken together Y_1 and Y_2 are connected via a ring having from 5 to 8 atoms in the ring structure which is hydrolyzed to hydroxy groups under physiological conditions;

X_1 represents a halogen;


X_2 and X_3 each represent a hydrogen or a halogen;

m is zero or an integer in the range of 1 to 8; and

n is an integer in the range of 1 to 8.

55. (Currently Amended) The method of claim 54, wherein

W represents $-\text{CH}=\text{NR}_5$,



R_5 represents a hydrogen, an alkyl, an alkenyl, an alkynyl, $-\text{C}(\text{X}_1)(\text{X}_2)\text{X}_3$, $-(\text{CH}_2)_m\text{-R}_7$, $-(\text{CH}_2)_n\text{-OH}$, $-(\text{CH}_2)_n\text{-O-alkyl}$, $-(\text{CH}_2)_n\text{-O-alkenyl}$, $-(\text{CH}_2)_n\text{-O-alkynyl}$, $-(\text{CH}_2)_n\text{-O}-(\text{CH}_2)_m\text{-R}_7$, $-(\text{CH}_2)_n\text{-SH}$, $-(\text{CH}_2)_n\text{-S-alkyl}$, $-(\text{CH}_2)_n\text{-S-alkenyl}$, $-(\text{CH}_2)_n\text{-S-alkynyl}$, $-(\text{CH}_2)_n\text{-S}-(\text{CH}_2)_m\text{-R}_7$, $-\text{C}(\text{O})\text{C}(\text{O})\text{NH}_2$, or $-\text{C}(\text{O})\text{C}(\text{O})\text{OR}'_7$;

R_7 represents, independently for each occurrence, a substituted or unsubstituted aryl, aralkyl, cycloalkyl, cycloalkenyl or heterocyclyl;

R'_7 represents, for each occurrence, hydrogen, or a substituted or unsubstituted alkyl, alkenyl, aryl, aralkyl, cycloalkyl, cycloalkenyl or heterocyclyl;

Y_1 and Y_2 can independently or together be hydroxyl, or taken together Y_1 and Y_2 are connected via a ring having from 5 to 8 atoms in the ring structure which is hydrolyzed to hydroxy groups under physiological conditions;

R_{50} represents O or S;


R_{51} represents N_3 , SH, NH_2 , NO_2 or OR'_7 ;

R_{52} represents hydrogen, a lower alkyl, an amine, OR'_7 , or a pharmaceutically acceptable salt, or R_{51} and R_{52} taken together with the phosphorous atom to which they are attached complete a heterocyclic ring having from 5 to 8 atoms in the ring structure;

X_1 represents a halogen; and

X_2 and X_3 each represent a hydrogen or a halogen.


56. (Original) The method of claim 54, wherein the ring A is represented by the formula




wherein,

n is an integer of 1 or 2.

57. (Previously Presented) The method of claim 54, wherein W represents



58. (Original) The method of claim 54, wherein R₁ represents



R₃₆ represents a small hydrophobic group and R₃₈ is hydrogen, or, R₃₆ and R₃₈ together form a 4-7 membered heterocycle including the N and the C α carbon, as defined for A above; and R₄₀ represents a C-terminally linked amino acid residue or amino acid analog, or a C-terminally linked peptide or peptide analog, or an amino-protecting group.


59. (Original) The method of claim 54, wherein R₂ is absent, or represents a small hydrophobic group.

60. (Original) The method of claim 54, wherein R₃ is a hydrogen, or a small hydrophobic group.

61. (Original) The method of claim 54, wherein R₅ is a hydrogen, or a halogenated lower alkyl.




62. (Original) The method of claim 54, wherein X₁ is a fluorine, and X₂ and X₃, if halogens, are fluorine.

63. (Original) The method of claim 54, wherein the inhibitor is represented by the general Formula (VIII):





wherein,

R_1 represents a C-terminally linked amino acid residue or amino acid analog, or a C-terminally

linked peptide or peptide analog, R_6 , R_6 , or R_6 ;

R_6 represents a hydrogen, a halogen, an alkyl, an alkenyl, an alkynyl, an aryl, $-(CH_2)_m-R_7$, $-(CH_2)_m-OH$, $-(CH_2)_m-O$ -alkyl, $-(CH_2)_m-O$ -alkenyl, $-(CH_2)_m-O$ -alkynyl, $-(CH_2)_m-O$ - $(CH_2)_m-R_7$, $-(CH_2)_m-SH$, $-(CH_2)_m-S$ -alkyl, $-(CH_2)_m-S$ -alkenyl, $-(CH_2)_m-S$ -alkynyl, $-(CH_2)_m-S$ - $(CH_2)_m-R_7$,



R_7 represents an aryl, a cycloalkyl, a cycloalkenyl, or a heterocycle;

R_8 and R_9 each independently represent hydrogen, alkyl, alkenyl, $-(CH_2)_m-R_7$, $-C(=O)$ -alkyl, $-C(=O)$ -alkenyl, $-C(=O)$ -alkynyl, or $-C(=O)-(CH_2)_m-R_7$,


or R_8 and R_9 taken together with the N atom to which they are attached complete a heterocyclic ring having from 4 to 8 atoms in the ring structure;

R_{11} and R_{12} each independently represent hydrogen, an alkyl, or a pharmaceutically acceptable salt, or R_{11} and R_{12} taken together with the O-B-O atoms to which they are attached complete a heterocyclic ring having from 5 to 8 atoms in the ring structure;

m is zero or an integer in the range of 1 to 8; and


n is an integer in the range of 1 to 8.

64. (Previously Presented) The method of claim 54, wherein the inhibitor is represented by the general Formula IX:





wherein

R₁ represents a C-terminally linked amino acid residue or amino acid analog, or a C-terminally



R₆ represents a hydrogen, a halogen, an alkyl, an alkenyl, an alkynyl, an aryl, $\text{-(CH}_2\text{)}_m\text{-R}_7$, $\text{-(CH}_2\text{)}_m\text{-OH}$, $\text{-(CH}_2\text{)}_m\text{-O-alkyl}$, $\text{-(CH}_2\text{)}_m\text{-O-alkenyl}$, $\text{-(CH}_2\text{)}_m\text{-O-alkynyl}$, $\text{-(CH}_2\text{)}_m\text{-O-(CH}_2\text{)}_m\text{-R}_7$, $\text{-(CH}_2\text{)}_m\text{-SH}$, $\text{-(CH}_2\text{)}_m\text{-S-alkyl}$, $\text{-(CH}_2\text{)}_m\text{-S-alkenyl}$, $\text{-(CH}_2\text{)}_m\text{-S-alkynyl}$, $\text{-(CH}_2\text{)}_m\text{-S-(CH}_2\text{)}_m\text{-R}_7$,



R₇ represents an aryl, a cycloalkyl, a cycloalkenyl, or a heterocycle;


R₈ and R₉ each independently represent hydrogen, alkyl, alkenyl, $\text{-(CH}_2\text{)}_m\text{-R}_7$, -C(=O)-alkyl , -C(=O)-alkenyl , -C(=O)-alkynyl , or $\text{-C(=O)-(CH}_2\text{)}_m\text{-R}_7$,

or R₈ and R₉ taken together with the N atom to which they are attached complete a heterocyclic ring having from 4 to 8 atoms in the ring structure;

m is zero or an integer in the range of 1 to 8; and


n is an integer in the range of 1 to 8.

65. (Currently Amended) The method of claim 54, wherein the inhibitor is represented by the general formula:





wherein,

R₁ represents a C-terminally linked amino acid residue or amino acid analog, or a C-terminally linked peptide, or peptide analog,



R₆ represents a hydrogen, a halogen, an alkyl, an alkenyl, an alkynyl, an aryl, $-(CH_2)_m-R_7$, $-(CH_2)_m-OH$, $-(CH_2)_m-O-alkyl$, $-(CH_2)_m-O-alkenyl$, $-(CH_2)_m-O-alkynyl$, $-(CH_2)_m-O-(CH_2)_m-R_7$, $-(CH_2)_m-SH$, $-(CH_2)_m-S-alkyl$, $-(CH_2)_m-S-alkenyl$, $-(CH_2)_m-S-alkynyl$, $-(CH_2)_m-S-(CH_2)_m-R_7$, or



R₇ represents an aryl, a cycloalkyl, a cycloalkenyl, or a heterocycle;

R₈ and R₉ each independently represent hydrogen, alkyl, alkenyl, $-(CH_2)_m-R_7$, $-C(=O)-alkyl$, $-C(=O)-alkenyl$, $-C(=O)-alkynyl$, or $-C(=O)-(CH_2)_m-R_7$, or


R₈ and R₉ taken together with the N atom to which they are attached complete a heterocyclic ring having from 4 to 8 atoms in the ring structure;

X₁, X₂, and X₃ each represent a hydrogen or a halogen;

m is zero or an integer in the range of 1 to 8; and

n is an integer in the range of 1 to 8.


66. (Currently Amended) The method of claim 54, wherein the inhibitor is represented by the general Formula Xa or Xb:



wherein,

A represents a 4- to 8-membered heterocycle including a N and a C α carbon;

W represents -CH=NR₅,




R₂ is absent or represents one or more substitutions to the ring A, each of which can

independently be a halogen, a lower alkyl, a lower alkenyl, a lower alkynyl, a carbonyl, a thiocarbonyl, an amino, an acylamino, an amido, a cyano, a nitro, an azido, a sulfate, a sulfonate, a sulfonamido, -(CH₂)_m-R₇, -(CH₂)_m-OH, -(CH₂)_m-O-lower alkyl, -(CH₂)_m-O-lower alkenyl, -(CH₂)_n-O-(CH₂)_m-R₇, -(CH₂)_m-SH, -(CH₂)_m-S-lower alkyl, -(CH₂)_m-S-lower alkenyl, or -(CH₂)_n-S-(CH₂)_m-R₇;

R₃ represents a hydrogen or a halogen, a lower alkyl, a lower alkenyl, a lower alkynyl, a

carbonyl, a thiocarbonyl, an amino, an acylamino, an amido, a cyano, a nitro, an azido, a sulfate, a sulfonate, a sulfonamido, -(CH₂)_m-R₇, -(CH₂)_m-OH, -(CH₂)_m-O-lower alkyl, -(CH₂)_m-O-lower alkenyl, -(CH₂)_n-O-(CH₂)_m-R₇, -(CH₂)_m-SH, -(CH₂)_m-S-lower alkyl, -(CH₂)_m-S-lower alkenyl, or -(CH₂)_n-S-(CH₂)_m-R₇;

R₅ represents a hydrogen, an alkyl, an alkenyl, an alkynyl, -C(X₁)(X₂)X₃, -(CH₂)_m-R₇, -(CH₂)_n-OH, -(CH₂)_n-O-alkyl, -(CH₂)_n-O-alkenyl, -(CH₂)_n-O-alkynyl, -(CH₂)_n-O-(CH₂)_m-R₇, -(CH₂)_n-SH, -(CH₂)_n-S-alkyl, -(CH₂)_n-S-alkenyl, -(CH₂)_n-S-alkynyl, -(CH₂)_n-S-(CH₂)_m-R₇, -C(O)C(O)NH₂, or -C(O)C(O)OR'₇;



R₇ represents, for each occurrence, a substituted or unsubstituted aryl, aralkyl, cycloalkyl, cycloalkenyl or heterocyclyl;

R'₇ represents, for each occurrence, hydrogen, or a substituted or unsubstituted alkyl, alkenyl, aryl, aralkyl, cycloalkyl, cycloalkenyl or heterocyclyl;

R₃₂ is a small hydrophobic group;

R₃₀ represents a C-terminally linked amino acid residue or amino acid analog, or a C-terminally linked peptide or peptide analog, or an amino-protecting group;

R₅₀ represents O or S;

R₅₁ represents N₃, SH, NH₂, NO₂ or OR'₇;

R₅₂ represents hydrogen, a lower alkyl, an amine, OR'₇, or a pharmaceutically acceptable salt, or R₅₁ and R₅₂ taken together with the phosphorous atom to which they are attached complete a heterocyclic ring having from 5 to 8 atoms in the ring structure;

Y₁ and Y₂ can independently or together be OH or an alkoxyl, or taken together Y₁ and Y₂ are connected via a ring having from 5 to 8 atoms in the ring structure which is hydrolyzed to hydroxy groups under physiological conditions;


X₁ represents a halogen;

X₂ and X₃ each represent a hydrogen or a halogen;

m is zero or an integer in the range of 1 to 8; and


n is an integer in the range of 1 to 8.

67. (Currently Amended) The method of any one of claims 38, 39, or 40, wherein the inhibitor is represented by the general Formula XI:




wherein,

W represents a functional group which reacts with an active site residue of the targeted protease selected from -CN, -CH=NR₅,



R₁ represents a C-terminally linked amino acid residue or amino acid analog, or a C-terminally linked peptide or peptide analog, or an amino-protecting group, or



R₃ represents hydrogen or a halogen, a lower alkyl, a lower alkenyl, a lower alkynyl, a carbonyl, a thiocarbonyl, an amino, an acylamino, an amido, a cyano, a nitro, an azido, a sulfate, a sulfonate, a sulfonamido, -(CH₂)_m-R₇, -(CH₂)_m-OH, -(CH₂)_m-O-lower alkyl, -(CH₂)_m-O-lower alkenyl, -(CH₂)_n-O-(CH₂)_m-R₇, -(CH₂)_m-SH, -(CH₂)_m-S-lower alkyl, -(CH₂)_m-S-lower alkenyl, or -(CH₂)_n-S-(CH₂)_m-R₇;

R₅ represents H, an alkyl, an alkenyl, an alkynyl, -C(X₁)(X₂)X₃, -(CH₂)_m-R₇, -(CH₂)_n-OH, -(CH₂)_n-O-alkyl, -(CH₂)_n-O-alkenyl, -(CH₂)_n-O-alkynyl, -(CH₂)_n-O-(CH₂)_m-R₇, -(CH₂)_n-SH, -(CH₂)_n-S-alkyl, -(CH₂)_n-S-alkenyl, -(CH₂)_n-S-alkynyl, -(CH₂)_n-S-(CH₂)_m-R₇, -C(O)C(O)NH₂, or -C(O)C(O)OR'₇;

R₆ represents a hydrogen, a halogen, an alkyl, an alkenyl, an alkynyl, an aryl, -(CH₂)_m-R₇, -(CH₂)_m-OH, -(CH₂)_m-O-alkyl, -(CH₂)_m-O-alkenyl, -(CH₂)_m-O-alkynyl, -(CH₂)_m-O-(CH₂)_m-R₇, -(CH₂)_m-SH, -(CH₂)_m-S-alkyl, -(CH₂)_m-S-alkenyl, -(CH₂)_m-S-alkynyl, or -(CH₂)_m-S-(CH₂)_m-R₇;

R₇ represents, for each occurrence, a substituted or unsubstituted aryl, aralkyl, cycloalkyl, cycloalkenyl or heterocyclyl;

R'₇ represents, for each occurrence, hydrogen, or a substituted or unsubstituted alkyl, alkenyl, aryl, aralkyl, cycloalkyl, cycloalkenyl or heterocyclyl;

R₆₁ and R₆₂, independently, represent small hydrophobic groups;

Y_1 and Y_2 can independently or together be OH or an alkoxyl, or taken together Y_1 and Y_2 are connected via a ring having from 5 to 8 atoms in the ring structure which is hydrolyzed to hydroxy groups under physiological conditions;

R_{50} represents O or S;

R_{51} represents N_3 , SH, NH_2 , NO_2 or OR'_7 ;

R_{52} represents hydrogen, a lower alkyl, an amine, OR'_7 , or a pharmaceutically acceptable salt, or R_{51} and R_{52} taken together with the phosphorous atom to which they are attached complete a heterocyclic ring having from 5 to 8 atoms in the ring structure;

X_1 represents a halogen;

X_2 and X_3 , independently for each occurrence, represent a hydrogen or a halogen;

m is zero or an integer in the range of 1 to 8; and

n is an integer in the range of 1 to 8.

68. (Currently Amended) The method of any one of claims 38-40, wherein the total dosage is less than 2000 mg.